Prosecution Insights
Last updated: April 19, 2026
Application No. 17/775,283

USE OF LIPID IN PREPARATION OF NUCLEIC ACID DELIVERY REAGENT AND RELATED PRODUCT THEREOF

Non-Final OA §102§112
Filed
Nov 08, 2022
Examiner
DAVIS, BRIAN J
Art Unit
1614
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
BEIJING BAISHIHEKANG PHARMACEUTICAL TECHNOLOGY (BSJPHARMA) CO., LTD
OA Round
1 (Non-Final)
85%
Grant Probability
Favorable
1-2
OA Rounds
1y 11m
To Grant
80%
With Interview

Examiner Intelligence

Grants 85% — above average
85%
Career Allow Rate
1317 granted / 1549 resolved
+25.0% vs TC avg
Minimal -5% lift
Without
With
+-4.8%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 11m
Avg Prosecution
47 currently pending
Career history
1596
Total Applications
across all art units

Statute-Specific Performance

§101
4.0%
-36.0% vs TC avg
§103
16.0%
-24.0% vs TC avg
§102
19.4%
-20.6% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1549 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restriction Inventor’s election, without traverse, of Compound 89 (specification page 29) as the species elected to begin prosecution is acknowledged. The election/restriction is hereby made FINAL. The examiner notes for clarity of the record that inventor has added new claim 105. The subject matter of this claim is encompassed by the original election/restriction requirement (an election of species across the entire claim set). Claim Objections Claim 56 is objected to because of the following informalities: the claim does not terminate with a period (after the table). Claims must begin with a capital letter and end with a period. MPEP 608.01(m). Appropriate correction is required. Inventor’s assistance is respectfully requested in correcting any other minor grammatical and/or spelling errors which may be present in the claim set. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1, 25, 29 and 53-55 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In the various definitions of variables L3, A, B and Q in the claims, it is unclear what a C1 alkenyl (“…C1-20 alkenyl…”) or a C1 heteroalkenyl (“…C1-20 heteroalkenyl…”) might be. This is so because an alkenyl ligand would necessitate at least 2 carbon atoms. Clarification is in order. Claims 2, 5, 24, 31, 36, 38, 50-52, 56, 63, 68 and 105 are also rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims all depend, or ultimately depend, from an indefinite claim yet do not relieve the indefiniteness. Dependent claims 2, 5, 24, 31, 36, 38, 50-52, 56, 63, 68 and 105 are also, therefore, indefinite. Markush Search All claims have been examined with respect to formal matters. The elected species has been searched and is deemed free of the prior art. The search was therefore expanded as called for under Markush examination practice, a compound-by-compound search, to include a single additional species. That species is: Trilinolenin (instant Compound 73). All claimed but as yet unexamined subject matter which does not read on the above species is hereby withdrawn from consideration, for purposes of this Office Action, as being drawn to non-elected subject matter. This subject matter will be rejoined as appropriate as the Markush examination progresses. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim 57, in so far as it reads on the above species, is rejected under 35 U.S.C. 102(a)(1) as being clearly anticipated by WO 2018/119514 A1. The reference teaches a method of transfecting cells with a nucleic acid utilizing a composition which comprises the triglyceride trilinolenin (abstract; page 4, lines 15ff and line 25). Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to BRIAN J DAVIS whose telephone number is (571)272-0638. The examiner can normally be reached M-F 8:30-5:00 PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Ali Soroush, can be reached at 571-272-9925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BRIAN J DAVIS/Primary Examiner, Art Unit 1614 12/14/2025
Read full office action

Prosecution Timeline

Nov 08, 2022
Application Filed
Dec 14, 2025
Non-Final Rejection — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12594226
COMPOSITION FOR AMELIORATING SKIN CONDITION
2y 5m to grant Granted Apr 07, 2026
Patent 12594257
MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS
2y 5m to grant Granted Apr 07, 2026
Patent 12594242
LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS
2y 5m to grant Granted Apr 07, 2026
Patent 12595280
PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS
2y 5m to grant Granted Apr 07, 2026
Patent 12576107
METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES
2y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
85%
Grant Probability
80%
With Interview (-4.8%)
1y 11m
Median Time to Grant
Low
PTA Risk
Based on 1549 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month